• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC - GALWAY SYNERGY II EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM; BIODEGRADABLE POLYMER DRUG ELUTING CORONARY STENT SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC - GALWAY SYNERGY II EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM; BIODEGRADABLE POLYMER DRUG ELUTING CORONARY STENT SYSTEM Back to Search Results
Model Number H7493926038220
Device Problems Occlusion Within Device (1423); Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Angina (1710); Atrial Fibrillation (1729); Congestive Heart Failure (1783); Dyspnea (1816); Fatigue (1849); Occlusion (1984); Reocclusion (1985); Chest Tightness/Pressure (2463)
Event Date 08/22/2017
Event Type  Injury  
Manufacturer Narrative
Device is a combination product.The device was not returned for analysis.A review of the manufacturing documentation found that all devices shipped from the batch conformed to the preventive measures / current controls as per the product specification.The root cause is anticipated procedural complications as this event is a known physiological effect of the procedure and is noted within the dfu.(b)(4).
 
Event Description
(b)(4) clinical study.It was reported that angina and coronary restenosis occurred.In (b)(6) 2016, clinical status assessment revealed the patient's qualifying condition as stable angina and the patient was referred for cardiac catheterization.Subsequently, the index procedure was performed.The target lesion was located in the proximal left circumflex (lcx) artery with 99% stenosis and was 12mm long with a reference vessel diameter of 2.25mm.The target lesion was treated with pre-dilatation and placement of 2.25x38mm synergy ii study stent.Following post-dilatation, the residual stenosis was 0%.On the same day, the patient was discharged on aspirin and clopidogrel.In (b)(6) 2017, the site reported an event of class iii angina.Nine days later, the 89% stenosis in proximal lcx was treated with drug-eluting stent placement, post which residual stenosis was 0%.Subsequently, an interventional procedure was also performed in response to the event.On the same day, the event was considered resolved.
 
Manufacturer Narrative
(b)(4).
 
Event Description
It was further reported that the target lesion was a long lesion located in the proximal/mid lcx to the second obtuse marginal (om2).In (b)(6) 2017, chronic atrial fibrillation was noted.Nine days after, focal in-stent restenosis at the proximal edge in mid lcx stent was noted and treated.The non-bsc stent in the mid lcx jailed the ostium of om1 and a 2.75x12mm non-bsc stent was implanted in an overlapping manner.There was small stenosis at the distal edge of 3.5 x 28 mm non-bsc stent which was treated with balloon angioplasty with good angiographic result.
 
Manufacturer Narrative
(b)(4).
 
Event Description
It was further reported that in (b)(6) 2017, the patient came with the complaints of chest pressure and dyspnea on exertion, fatigue and class ii chronic heart failure (chf).The patient was referred for cardiac catheterization with possible percutaneous coronary intervention (pci) to assess ischemic induced chf and stent restenosis.Eight days later, 80-89% stenosis in mid left circumflex (lcx) was treated with pre-dilatation and placement of 2.75 x 12 mm non-bsc drug eluting stent.Following post dilatation, the residual stenosis was 0% with timi 3 flow.Post stent deployment in mid lcx, stenosis in om1 got worsened to 80% which was treated with pre-dilatation and placement of 3.5 x 28 mm non-bsc stent.Following post dilatation, the residual stenosis was 0% with timi 3 flow.Patient was sent home with discharge instructions.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNERGY II EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM
Type of Device
BIODEGRADABLE POLYMER DRUG ELUTING CORONARY STENT SYSTEM
Manufacturer (Section D)
BOSTON SCIENTIFIC - GALWAY
Manufacturer (Section G)
BOSTON SCIENTIFIC - GALWAY
Manufacturer Contact
sonali arangil
one scimed place
maple grove, MN 55311
7634941700
MDR Report Key6899745
MDR Text Key87589878
Report Number2134265-2017-09504
Device Sequence Number1
Product Code NIQ
UDI-Device Identifier08714729840381
UDI-Public08714729840381
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P150003
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 09/07/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/27/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date07/07/2017
Device Model NumberH7493926038220
Device Catalogue Number39260-3822
Device Lot Number19472110
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received11/29/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured07/27/2016
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age67 YR
-
-